Home > Insider Trading > Filing (0001562180-21-007738)

Filing Details

Accession Number:: 0001562180-21-007738
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-12-16 21:04:36
Reporting Period:: 2021-12-14

Accepted Time:: 2021-12-16 21:04:36
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1689813	Biohaven Pharmaceutical Holding Co Ltd.	BHVN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1785732	Elyse Stock	C/O Biohaven Pharmaceuticals, Inc. 215 Church Street New Haven CT 06510	Chief Medical Officer	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Shares	Acquisiton	2021-12-14	3,362	$20.79	10,829	No	4	M	Direct
Common Shares	Acquisiton	2021-12-14	3,577	$10.82	14,406	No	4	M	Direct
Common Shares	Disposition	2021-12-14	6,939	$105.02	7,467	No	4	S	Direct
Common Shares	Acquisiton	2021-12-15	6,996	$20.79	14,463	No	4	M	Direct
Common Shares	Acquisiton	2021-12-15	14,923	$10.82	29,386	No	4	M	Direct
Common Shares	Disposition	2021-12-15	20,330	$105.43	9,056	No	4	S	Direct
Common Shares	Disposition	2021-12-15	1,589	$106.17	7,467	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Employee Stock Option (Right to Buy)	Disposition	2021-12-14	3,362	$0.00	3,362	$20.79
Common Shares	Employee Stock Option (Right to Buy)	Disposition	2021-12-14	3,577	$0.00	3,577	$10.82
Common Shares	Employee Stock Option (Right to Buy)	Disposition	2021-12-15	6,996	$0.00	6,996	$20.79
Common Shares	Employee Stock Option (Right to Buy)	Disposition	2021-12-15	14,923	$0.00	14,923	$10.82

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
18,534	2027-12-06	No	4	M	Direct
14,923	2027-04-05	No	4	M	Direct
11,538	2027-12-06	No	4	M	Direct
0	2027-04-05	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Shares	2,187	Indirect	By Spouse

Footnotes

These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.00 - $105.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.00 - $105.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.00 - $106.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
The shares underlying this option vested as to 25% of the shares on December 7, 2018, the grant date, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date.
The shares underlying this option vested as to 25% of the shares on April 6, 2017, the grant date, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date